ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality

被引:11
|
作者
Dun, Yiting [1 ]
Huang, Gang [1 ,2 ]
Liu, Jianjun [1 ]
Wei, Weijun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200217, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China
基金
中国国家自然科学基金;
关键词
ImmunoPET; Hematological malignancies; Antibody; Lymphoma; Leukemia; Multiple myeloma; POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR CXCR4 EXPRESSION; TRANSGENIC MOUSE MODEL; RADIATION-DOSIMETRY; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; IN-VIVO; B-CELLS; LYMPHOMA; THERAPY;
D O I
10.1016/j.drudis.2021.11.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immuno-positron emission tomography (immunoPET) imaging is a paradigm-shifting imaging technique for whole-body and all-lesion tumor detection, based on the combined specificity of tumor-targeting vectors [e.g., monoclonal antibodies (mAbs), nanobodies, and bispecific antibodies] and the sensitivity of PET imaging. By noninvasively, comprehensively, and serially revealing heterogeneous tumor antigen expression, immunoPET imaging is gradually improving the theranostic prospects for hematological malignancies. In this review, we summarize the available literature regarding immunoPET in imaging hematological malignancies. We also highlight the pros and cons of current conjugation strategies, and modular chemistry that can be leveraged to develop novel immunoPET probes for hematological malignancies. Lastly, we discuss the use of immunoPET imaging in guiding antibody drug development.
引用
收藏
页码:1196 / 1203
页数:8
相关论文
共 50 条
  • [31] Discovery and preclinical development of selective JAK inhibitors for the treatment of hematological malignancies
    Fridman, S.
    Li, J.
    Liu, P.
    Caulder, E.
    Crowgey, E.
    Favata, M.
    Guoen, G.
    Li, Y.
    Covington, M.
    Rodgers, J.
    Combs, A.
    Yeleswaram, S.
    Newton, R.
    Scherle, P.
    Vaddi, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 117 - 117
  • [32] Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
    Duran-Struuck, Reimon
    Huang, Christene A.
    Matar, Abraham J.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [33] Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice
    Ma, Haiqing
    Mallampati, Saradhi
    An, Gang
    Wang, Jin
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [34] Syk inhibitors in clinical development for hematological malignancies
    Delong Liu
    Aleksandra Mamorska-Dyga
    Journal of Hematology & Oncology, 10
  • [35] Clinical Proteomics: A Promise Becoming Reality
    Gillette, Michael A.
    Jimenez, Connie R.
    Carr, Steven A.
    MOLECULAR & CELLULAR PROTEOMICS, 2024, 23 (02)
  • [36] The functions and clinical significance of circRNAs in hematological malignancies
    Xiangxiang Zhou
    Linquan Zhan
    Kai Huang
    Xin Wang
    Journal of Hematology & Oncology, 13
  • [37] The functions and clinical significance of circRNAs in hematological malignancies
    Zhou, Xiangxiang
    Zhan, Linquan
    Huang, Kai
    Wang, Xin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [38] MULTIDRUG RESISTANCE - CLINICAL RELEVANCE IN HEMATOLOGICAL MALIGNANCIES
    KAYE, SB
    KERR, DJ
    BLOOD REVIEWS, 1991, 5 (01) : 38 - 41
  • [39] BACTEREMIA AND CANDIDEMIA IN HEMATOLOGICAL MALIGNANCIES - CLINICAL FINDINGS
    HOVGAARD, D
    SKINHOJ, P
    BANGSBORG, J
    BRUUN, B
    HANSEN, MM
    NISSEN, NI
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1988, 20 (05) : 495 - 501
  • [40] Syk inhibitors in clinical development for hematological malignancies
    Liu, Delong
    Mamorska-Dyga, Aleksandra
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10